Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

This article was originally published in PharmAsia News

Executive Summary

Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan

Related Content

Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Otsuka, Bristol-Myers Squibb Withdraw Abilify Extension Application In Europe
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Bristol/AZ Saxagliptin Clears Cardiovascular Safety Hurdle; Approval Timing Still Uncertain
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Mead Johnson Set Loose To Navigate Market, Shifting Economic Winds
Bristol Reports Strong 2008 Earnings But Sharp Patent Cliffs Loom
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts